Publication

Video

Supplements and Featured Publications

Emerging Treatments and Clinical Challenges in Myelodysplastic Syndromes: ASCO 2021 and EHA 2021 Updates
Volume1
Issue 1

Dr. Sallman on the Efficacy of Pevonedistat Plus Azacitidine in Higher-Risk MDS

David Sallman, MD, discusses the efficacy of pevonedistat plus azacitidine in higher-risk myelodysplastic syndrome.

David Sallman, MD, assistant member, Department of Malignant Hematology, Moffitt Cancer Center, discusses the efficacy of pevonedistat plus azacitidine in higher-risk myelodysplastic syndrome (HR-MDS).

Findings from the randomized, proof-of-concept phase 2 study (NCT02610777) demonstrated a clinically meaningful improvement in overall survival and event-free survival with the combination of pevonedistat plus azacitidine vs azacitidine alone in patients with HR-MDS/chronic myelomonocytic leukemia or low-blast acute myeloid leukemia, Sallman says.

The overall response rate (ORR) was 70.9% with pevonedistat/azacitidine vs 60.4% with azacitidine alone in the overall patient population. The ORR was 79.3% vs 56.7%, respectively, for patients with HR-MDS. The median duration of response was 34.6 months compared with 13.1 months, respectively, in patients with HR-MDS, Sallman concludes.

Related Videos
J. Bradley Elder, MD
Rimas V. Lukas, MD
Shubham Pant, MD, MBBS
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Howard S. Hochster, MD, FACP,
John H. Strickler, MD
Brandon G. Smaglo, MD, FACP
Cedric Pobel, MD
Ruth M. O’Regan, MD